The FDA has approved abiraterone, a CYP17A1 inhibitor, and enzalutamide, a potent anti-androgen, as second-line treatments for metastatic prostate cancer, but during treatment, prostate cancer often develops drug resistance and progresses to castration Resistant prostate cancer (CRPC). AR-V7-negative patients treated with abiraterone and enzalutamide had significantly shorter clinical or radiographic progression-free survival and overall survival than AR-V7-positive patients. Studies have shown that AR-V7 is involved in the development of resistance to abiraterone and enzalutamide. The AR-V7 mutation detection kit independently developed by MEDx Translational Medicine based on dPCR platform is used for AR-V7 detection.
Xinyi TD-1 and ABI Quantstudio 3D
√Primary resistance to abiraterone/enzalutamide in newly diagnosed CRPC population
√Detect secondary drug resistance in CRPC patients taking abiraterone/enzalutamide
√ Predict the possible benefit of mHSPC patients from ADT combined with abiraterone/enzalutamide treatment
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D